[Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)].

According to the data of seventh national census in China, the elderly population (≥60 years old) accounts for 18.7% (260.4 million) of the total population in 2020. Among them, 30% are diabetes (78.13 million, and more than 95% being type 2 diabetes). Diabetic complications caused by poor glycemic control are the main risk factors influencing the healthy and survival of the elderly, and thus, diabetes prevention and treatment has been to be one of the key actions of Healthy China (2019-2030). The present guideline-"Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)" is formulated on the basis of the " Expert consensus of the diagnosis and treatment measures for Chinese elderly patients with type 2 diabetes (2018 edition)" and summarizes the domestic and foreign related guidelines for elderly diabetes and research information. The aim of the guide is to optimize the elderly diabetes prevention and control concept, to promote the implementation of standardized clinical prevention, diagnosis and treatment strategy and to improve the level of overall management of diabetes in the elderly.中国第七次人口普查数据显示，2020年我国老年人口（≥60岁）占总人口的18.7%（2.604亿），其中约30%的老年人是糖尿病患者（7 813万，95%以上是2型糖尿病）。糖尿病控制欠佳所致并发症是老年人健康生存的主要危险因素，糖尿病防治已是健康中国（2019—2030年）的重点行动之一。延续“中国老年2型糖尿病诊疗措施专家共识（2018年版）”的主旨，制订“中国老年2型糖尿病防治临床指南（2022年版）”，汇总国内外老年糖尿病相关指南和研究信息，旨在进一步优化老年糖尿病防治理念，促进规范化预防、诊疗临床措施的实施，不断提高老年糖尿病总体管理水平。.